Infectious diseases are some of the most prevalent and intractable in the world, presenting unique challenges such as treatment resistance and, in some instances, high transmission. In the wake of a global pandemic, the world is on alert for new contagions and ambitiously seeking new solutions for treatment and prevention. Grifols is laser focused on providing rapid immune coverage in some of the most life-threatening pathogenic conditions.

Expanding our infectious disease treatments

Grifols has invested in treatments for infectious diseases, including hepatitis B virus (HBV), rabies, Zika virus and Ebola.1

Our Biotest group is also working on a breakthrough plasma protein, trimodulin, a unique polyvalent Ig product including IgG, IgA as well as IgM, to reduce dysregulated immune responses in patients with severe pneumonia. A Phase 3 clinical trial is focused on severe community-acquired pneumonia (sCAP), one of the leading causes of death worldwide,2 in patients with high inflammatory markers. A second Phase 3 trial is focusing on a specific subgroup of hospitalized COVID-19 patients with early systemic inflammation.  

The company is also working on a potential treatment for human cytomegalovirus (CMV) infection during pregnancy to prevent prenatal transmission from the mother to her unborn child, using Cytotect®, a plasma-derived polyclonal Ig preparation (CMVIg) containing large amounts of anti-CMV antibodies.

Developing a new type of drug – recombinant polyclonal antibodies

Our GigaGen group is taking a groundbreaking approach to treat HBV, a widespread disease with significant morbidity. Despite currently available therapies and vaccines, HBV affects more than 296 million people worldwide,3 resulting in more than 800,000 deaths each year.3

The HBV recombinant polyclonal drug product in development consists of more than 1,000 anti-HBV antibodies made in the laboratory by reproducing the antibodies generated during a natural immune response. This approach could ensure that the therapy covers the large diversity of circulating HBV variants, given that the diversity of antibodies is selected and manufactured in the laboratory and does not need to be isolated from plasma.

GigaGen technology will be used for the development of recombinant polyclonal antibody drugs for a wide range of infectious diseases.

1 Serra A, Marzo N, Pons B, Maduell P, López M, Grancha S. Characterization of antibodies in human immunoglobulin products from different regions worldwide. Int J Infect Dis. 2021;104:610-616. doi:10.1016/j.ijid.2021.01.034

2 Wunderink RG, Waterer GW. Clinical practice. Community-acquired pneumonia. N Engl J Med. 2014;370(6):543-51. doi: 10.1056/NEJMcp1214869

3 WHO (https://www.who.int/news-room/fact-sheets/detail/hepatitis-b)